Ralf J Hosse
Overview
Explore the profile of Ralf J Hosse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
970
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lotz G, Lutz A, Martin-Facklam M, Hansbauer A, Schick E, Moessner E, et al.
Front Immunol
. 2024 Jun;
15:1406353.
PMID: 38881900
An appropriately designed pharmacokinetic (PK) assay that is sensitive for anti-drug antibody (ADA) impact on relevant exposure is an alternative strategy to understand the neutralizing potential of ADAs. However, guidance...
2.
Wang C, Petersone L, Edner N, Heuts F, Ovcinnikovs V, Ntavli E, et al.
Nat Commun
. 2023 Sep;
14(1):5724.
PMID: 37714833
No abstract available.
3.
Wang C, Petersone L, Edner N, Heuts F, Ovcinnikovs V, Ntavli E, et al.
Nat Commun
. 2022 Nov;
13(1):6757.
PMID: 36347877
Blockade of CD28 costimulation with CTLA-4-Ig/Abatacept is used to dampen effector T cell responses in autoimmune and transplantation settings. However, a significant drawback of this approach is impaired regulatory T...
4.
Waldhauer I, Gonzalez-Nicolini V, Freimoser-Grundschober A, Nayak T, Fahrni L, Hosse R, et al.
MAbs
. 2021 May;
13(1):1913791.
PMID: 33974508
Simlukafusp alfa (FAP-IL2v, RO6874281/RG7461) is an immunocytokine comprising an antibody against fibroblast activation protein α (FAP) and an IL-2 variant with a retained affinity for IL-2Rβγ > IL-2 Rβγ and...
5.
Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, et al.
Sci Transl Med
. 2019 Jun;
11(496).
PMID: 31189721
Endogenous costimulatory molecules on T cells such as 4-1BB (CD137) can be leveraged for cancer immunotherapy. Systemic administration of agonistic anti-4-1BB antibodies, although effective preclinically, has not advanced to phase...
6.
Peterson L, Bell C, Howlett S, Pekalski M, Brady K, Hinton H, et al.
J Autoimmun
. 2018 Nov;
95:1-14.
PMID: 30446251
Susceptibility to multiple autoimmune diseases is associated with common gene polymorphisms influencing IL-2 signaling and T function, making T-specific expansion by IL-2 a compelling therapeutic approach to treatment. As an...
7.
Seckinger A, Delgado J, Moser S, Moreno L, Neuber B, Grab A, et al.
Cancer Cell
. 2017 Mar;
31(3):396-410.
PMID: 28262554
We identified B cell maturation antigen (BCMA) as a potential therapeutic target in 778 newly diagnosed and relapsed myeloma patients. We constructed an IgG-based BCMA-T cell bispecific antibody (EM801) and...
8.
Brunker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller C, et al.
Mol Cancer Ther
. 2016 Apr;
15(5):946-57.
PMID: 27037412
Dysregulated cellular apoptosis and resistance to cell death are hallmarks of neoplastic initiation and disease progression. Therefore, the development of agents that overcome apoptosis dysregulation in tumor cells is an...
9.
Schanzer J, Wartha K, Moessner E, Hosse R, Moser S, Croasdale R, et al.
MAbs
. 2016 Mar;
8(4):811-27.
PMID: 26984378
The epidermal growth factor receptor (EGFR) and the insulin-like growth factor-1 receptor (IGF-1R) play critical roles in tumor growth, providing a strong rationale for the combined inhibition of IGF-1R and...
10.
Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, et al.
Clin Cancer Res
. 2016 Feb;
22(13):3286-97.
PMID: 26861458
Purpose: CEA TCB is a novel IgG-based T-cell bispecific (TCB) antibody for the treatment of CEA-expressing solid tumors currently in phase I clinical trials (NCT02324257). Its format incorporates bivalent binding...